The reverse split authorization (up to 1:250) signals potential Nasdaq compliance efforts — monitor for announcement of specific ratio and timing. The enhanced change-in-control severance provisions may indicate the board is positioning for a sale process. No operating or financial data was provided; wait for the next 10-Q for revenue/cash runway updates.
Price Chart
Executive Summary
Revelation Biosciences filed an 8-K covering: (1) amended CEO/CFO employment agreements with enhanced change-in-control severance (2x base + bonus, 18-month COBRA, full equity vesting), (2) bylaw amendments adding universal proxy rules, a formal 'Cause' definition, and an emergency CEO/CFO succession framework, and (3) annual meeting results including approval of a reverse stock split (ratio up to 1:250) and ratification of Baker Tilly as auditor. The $4M micro-cap's board is entrenching governance provisions and increasing executive golden parachutes as the company appears to prepare for potential restructuring or a sale process.
Key Facts
- CEO James Rolke and CFO Chester Zygmont III entered new 3-year employment agreements with 2x base + target bonus change-in-control severance (up from 1x), plus 18-month COBRA and full equity acceleration
- Stockholders approved a reverse stock split at any ratio between 1:2 and 1:250, within one year, with no further stockholder vote required
- Bylaws amended to add a formal 'Cause' definition (requiring independent-board determination) and emergency succession for CEO/CFO vacancies
- Annual meeting votes: 519,169 for Jennifer Carver as Class A director (vs 24,779 against, 263,081 withheld); 1,786,623 for reverse split authorization
- No financial data (revenue, EPS, margins, cash flow) was provided in the filing
- Market cap is $4M with 86% analyst bullishness but substantial broker non-votes (1,427,319 on director election) suggesting retail-dominated shareholder base
Financial Impact
No financial data reported in filing. CEO base salary disclosed at $625,000 with 55% target bonus; CFO terms not disclosed. Reverse split authorized up to 1:250, which could significantly affect share count and per-share metrics.
Risk Factors
- Reverse stock split risks: liquidity reduction, potential secondary offering, warrant adjustment complexities
- Micro-cap with $4M market cap faces Nasdaq delisting if bid price stays below $1.00
- Enhanced golden parachutes could reduce board discipline in a sale process
- No operating revenue reported — cash runway and burn rate are unknown from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-281200 |
| Document: 0001193125-26-281200-index.html | 0001193125-26-281200 |
| Document: 0001193125-26-281200.txt | 0001193125-26-281200 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | 8-K | $1.07 $0.9304 | ▼ −13.05% | ▼ −12.93% | $0.7636 (−28.64%) |
Jun 24, 2026 14w ago | 8-K | $0.9600 $1.07 | ▲ +11.46% | ▲ +10.93% | $0.7636 (−20.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access